| Writing Group Member |
Employment | Research Grant | Other Research Support |
Speakers’ Bureau/ Honoraria |
Expert Witness |
Ownership Interest |
Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Mark A. Hlatky | Stanford University School of Medicine | Aviir, Inc* | None | None | None | None | GE Healthcare†; Blue Cross Blue Shield Technology Evaluation Center† | None |
| Philip Greenland | Northwestern University Feinberg School of Medicine | NIH† | None | None | None | None | GE/Toshiba*; Pfizer* | None |
| Donna K. Arnett | University of Alabama at Birmingham | None | None | None | None | None | None | None |
| Christie M. Ballantyne | Baylor College of Medicine | Abbott†; ActivBiotics†; Gene Logic†; GlaxoSmithKline†; Integrated Therapeutics†; Merck†; Pfizer†; Sanofi-Synthelabo†; Schering-Plough†; Takeda† | None | AstraZeneca*; Merck*; Pfizer*; Reliant*; Schering-Plough* | None | None | Abbott*; AstraZeneca*; Atherogenics*; GlaxoSmithKline*; Merck†; Merck/Schering-Plough*; Novartis*; Pfizer*; Reliant†; Sanofi-Synthelabo*; Schering-Plough*; Takeda* | None |
| Michael H. Criqui | University of California, San Diego | None | None | None | None | None | None | None |
| Mitchell S.V. Elkind | Columbia University Medical Center | DiaDexus, Inc†; BMS-Sanofi†; NINDS† | None | Boehringer-Ingelheim†; BMS-Sanofi* | None | None | GlaxoSmithKline*; Merck* | None |
| Alan S. Go | Kaiser Permanente of Northern California | Aviir, Inc†; GeneNews, Inc†; NHLBI† | None | None | None | None | None | None |
| Frank E. Harrell, Jr | Vanderbilt University | Supported in part by Vanderbilt CTSA grant 1 UL1 RR024975 from the National Center for Research Resources, National Institutes of Health | None | None | None | None | None | None |
| Yuling Hong‡ | American Heart Association | None | None | None | None | None | None | None |
| Barbara V. Howard | Medstar Research Institute | None | None | None | None | None | None | None |
| Virginia J. Howard | University of Alabama at Birmingham | NINDS† | None | None | None | None | None | None |
| Priscilla Y. Hsue | University of California, San Francisco | None | None | None | None | None | None | None |
| Christopher M. Kramer | University of Virginia Health System | Astellas†; GlaxoSmithKline† | Merck*; Siemens Medical Solutions† | Merck Schering-Plough* | None | None | Siemens Medical Solutions* | None |
| Joseph P. McConnell | Mayo Clinic | NHLBI† | None | None | None | None | None | None |
| Sharon-Lise T. Normand | Harvard Medical School | None | None | None | None | None | MA Blue Cross Blue Shield Performance Measure Advisory Panel Member*; Kaiser Permanente Colorado Institute for Health Research* | None |
| Christopher J. O’Donnell | NHLBI-Framingham Heart Study | None | None | None | None | None | None | None |
| Sidney C. Smith, Jr | University of North Carolina School of Medicine | None | None | None | None | None | None | None |
| Peter W.F. Wilson | Emory University School of Medicine | GlaxoSmithKline†; Sanofi-Aventis† | None | None | None | None | GlaxoSmithKline* | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.
‡
Dr Hong is now with the Centers for Disease Control and Prevention, Atlanta, Ga.